These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 29316027)
21. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
22. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. de Vries AC; Stam RW; Kratz CP; Zenker M; Niemeyer CM; van den Heuvel-Eibrink MM; Haematologica; 2007 Nov; 92(11):1574-5. PubMed ID: 18024410 [TBL] [Abstract][Full Text] [Related]
23. The Clinical Landscape of NRAS- mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome. Pabari R; Chun K; Naqvi A J Pediatr Hematol Oncol; 2023 Apr; 45(3):e401-e405. PubMed ID: 35665722 [TBL] [Abstract][Full Text] [Related]
24. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Caye A; Rouault-Pierre K; Strullu M; Lainey E; Abarrategi A; Fenneteau O; Arfeuille C; Osman J; Cassinat B; Pereira S; Anjos-Afonso F; Currie E; Ariza-McNaughton L; Barlogis V; Dalle JH; Baruchel A; Chomienne C; Cavé H; Bonnet D Leukemia; 2020 Jun; 34(6):1658-1668. PubMed ID: 31776464 [TBL] [Abstract][Full Text] [Related]
25. Integrated molecular profiling of juvenile myelomonocytic leukemia. Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595 [TBL] [Abstract][Full Text] [Related]
26. After 95 years, it's time to eRASe JMML. Meynier S; Rieux-Laucat F Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238 [TBL] [Abstract][Full Text] [Related]
27. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399 [TBL] [Abstract][Full Text] [Related]
28. Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder. Hyakuna N; Muramatsu H; Higa T; Chinen Y; Wang X; Kojima S Pediatr Blood Cancer; 2015 Mar; 62(3):542-4. PubMed ID: 25283271 [TBL] [Abstract][Full Text] [Related]
30. [Identification of two novel WASP gene mutations in 3 boys with Wiskott-Aldrich syndrome]. Jiang LP; Xu YH; Yang XQ; Liu EM; Wang LJ; Lau YL; Chan KW Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):590-3. PubMed ID: 14744380 [TBL] [Abstract][Full Text] [Related]
31. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Locatelli F; Algeri M; Merli P; Strocchio L Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013 [TBL] [Abstract][Full Text] [Related]
33. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now? De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370 [TBL] [Abstract][Full Text] [Related]
34. How I treat juvenile myelomonocytic leukemia. Locatelli F; Niemeyer CM Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399 [TBL] [Abstract][Full Text] [Related]
35. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299 [TBL] [Abstract][Full Text] [Related]
36. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia. De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880 [TBL] [Abstract][Full Text] [Related]
37. Wiskott-Aldrich syndrome is an important differential diagnosis in male infants with juvenile myelomonocytic leukemialike features. Watanabe N; Yoshimi A; Kamachi Y; Kawabe T; Muramatsu H; Matsumoto K; Manabe A; Kojima S; Kato K J Pediatr Hematol Oncol; 2007 Dec; 29(12):836-8. PubMed ID: 18090932 [TBL] [Abstract][Full Text] [Related]
38. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965 [TBL] [Abstract][Full Text] [Related]
39. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Koike K; Matsuda K Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786 [TBL] [Abstract][Full Text] [Related]
40. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Hecht A; Meyer JA; Behnert A; Wong E; Chehab F; Olshen A; Hechmer A; Aftandilian C; Bhat R; Choi SW; Chonat S; Farrar JE; Fluchel M; Frangoul H; Han JH; Kolb EA; Kuo DJ; MacMillan ML; Maese L; Maloney KW; Narendran A; Oshrine B; Schultz KR; Sulis ML; Van Mater D; Tasian SK; Hofmann WK; Loh ML; Stieglitz E Haematologica; 2022 Jan; 107(1):178-186. PubMed ID: 33375775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]